Keyword: Nektar Therapeutics
The phase 1/2 results show the efficacy seen at 12 months has persisted, providing early evidence of durable responses.
7. Thomas Lynch, Bristol-Myers Squibb
Two months after Nektar Therapeutics handed off its lead pain drug to a new subsidiary, the FDA is postponing an advisory panel meeting for that drug.
Nektar Therapeutics has posted updated data on its NKTR-214-Opdivo cocktail in first-line melanoma that features four more complete responses.
Nektar Therapeutics created Inheris Biopharma, a new subsidiary that will take over the launch of Nektar’s pain drug, NKTR-181.
Nektar has had a mixed few months as data fed through for its lead cancer drug NKTR-214, but new data in bladder cancer should help longer term
As we near the end of the year, we take a look back over the biggest stories of 2018 and gauge what readers found the most interesting.
Dermavant hires Zavodnick as CEO; Bayer VP to lead Matoke Pharma; and Genentech I-O leader Wei Lin will head up Nektar's oncology work.
Nektar Therapeutics poached Genentech immunotherapy leader Wei Lin to head up its oncology program and serve as VP of clinical development.
After posting sinking response rates, Nektar unveiled new results for its NKTR-214 and Opdivo melanoma therapy that showed rates holding just steady.